Showing 9411-9420 of 21412 results for "".
Unraveling the Mechanism: How Ocrelizumab Impacts Cortical Lesions in MS
https://reachmd.com/programs/neurofrontiers/unraveling-the-mechanism-how-ocrelizumab-impacts-cortical-lesions-in-ms/32367/While B-cell follicles in the brain’s meninges were previously suspected to drive cortical lesions in multiple sclerosis (MS), studies show ocrelizumab has little impact on B-cell follicles—yet it still significantly reduces cortical lesions. This suggests that another, yet-to-be-understood B-cell-mATTR-CM Screening: How Economic Factors Can Impact Care
https://reachmd.com/programs/heart-matters/attr-cm-screening-how-economic-factors-can-impact-care/32901/Economic factors can limit accessibility to screening for transthyretin amyloidosis. Hear expert insights on potential solutions to these challenges.Cognitive Impairment in MS: Mitigating Impacts to Optimize Brain Health
https://reachmd.com/programs/neurofrontiers/cognitive-impairment-in-ms-mitigating-impacts-to-optimize-brain-health/32370/Learn about how cognitive impairment can affect patients with multiple sclerosis and discover ways to support their cognitive function.Multiple Sclerosis Explained: Understanding Its Epidemiology
https://reachmd.com/programs/neurofrontiers/multiple-sclerosis-explained-understanding-its-epidemiology/32371/Hear about how multiple sclerosis impacts patients, and learn about genetic and environmental factors associated with the onset of the disease.The Impact of Clascoterone Topical Cream, 1%: The US Experience 4 Years After Approval and Clinical Expectations for Acne Patients in Other Regions of the World
https://reachmd.com/topics/acne-rosacea/Impact-Clascoterone-Topical-Cream/32830/Clascoterone topical cream, 1% (Winlevi), approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older. The safety and efficacy were supported by two succeManaging Extraintestinal Manifestations in IBD
https://reachmd.com/programs/gi-insights/managing-extraintestinal-manifestations-in-ibd/18001/Extraintestinal manifestations in IBD are common and can impact a patient’s quality of life. Here’s how to manage them.Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
https://reachmd.com/programs/acc-action-center/increasing-the-use-of-sglt2i-and-glp1ra-with-remote-program-in-t2d-high-cv-or-kidney-risk/24310/ACC.24 - Can the way patients are educated and medications prescribed be improved? Alexander Blood shares the results of the DRIVE study.Epoprostenol: A Look at a Last-Line Inhalation Therapy for ARDS
https://reachmd.com/programs/clinicians-roundtable/epoprostenol-a-look-at-a-last-line-inhalation-therapy-for-ards/16291/Learn about the efficacy and safety of inhaled epoprostenol as a last-line treatment strategy for patients with acute respiratory distress syndrome.Detecting MS Biomarkers: An IgG Antibody Blood Test Offers 90% Accuracy
https://reachmd.com/programs/neurofrontiers/detecting-ms-biomarkers-an-igg-antibody-blood-test-offers-90-accuracy/16252/Dive into the findings and potential impacts of a recent study that evaluated an IgG antibody blood test’s ability to identify MS biomarkers.Caring for Immunocompromised Patients: Reminders Heading into Flu Season
https://reachmd.com/programs/clinicians-roundtable/caring-for-immunocompromised-patients-reminders-heading-into-flu-season/16175/What can we do to help patients who are the most vulnerable to reduce their risk of infections while improving health outcomes? Read more.